We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




No Link Between Breast Cancer and Oral Contraceptives

By HospiMedica staff writers
Posted on 01 Aug 2002
A large, multicenter study has found that women who took oral contraceptives at some time in their lives are no more likely to develop breast cancer between the ages of 35 and 64 than other women the same age. More...
The study appeared in the June 27, 2002, issue of The New England Journal of Medicine.

Researchers interviewed more than 9,200 women between 35 and 64 in various parts of the United States. About half had been diagnosed with breast cancer, while the other half had not. Interviewers asked both groups questions about their use of oral contraceptives and other hormones as well as other health-related questions. They found that women who had used any type of oral contraception did not have a greater risk of developing breast cancer than women who had not used oral contraception. Oral contraceptive use among women with a family history of breast cancer was not associated with a significantly increased breast cancer risk, nor was the initiation of oral contraceptive use at a young age.

About 89% of US women born since 1945 have used oral contraceptives, and large numbers of them are now reaching the ages of greatest breast cancer risk. "We conducted this study to resolve the long-standing concern that oral contraceptive use might be associated with an increased risk of breast cancer late in life. Our study provides scientific evidence that there is no such association,” said Robert Spirtas, Dr.P.H., chief of the contraception and reproductive health branch of the US National Institute of Child Health and Human Development (NICHD), which sponsored the study.




Related Links:
NICHD

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.